Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4545
- Book/Share 8.5908
- PB 5.4708
- Debt/Equity 2.9466
- CurrentRatio 1.2789
- ROIC 0.1085
- MktCap 95323147200.0
- FreeCF/Share 6.4431
- PFCF 7.2844
- PE 17.5553
- Debt/Assets 0.5544
- DivYield 0.0521
- ROE 0.3193
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
Read More
BMY Reports Positive Data on Sotyktu From Arthritis Study
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
Read More
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization Officer Christopher S. Boerner - CEO & Chairman Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider All right.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
Read More
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types.
Read More
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327, targeting large cancer markets, with a deal structure that limits BMY's downside risk. BMY's established cash flows, low payout ratio, and current low valuation make it a safer, income-generating pick versus higher-risk, growth-oriented BioNTech.
Read More
Bristol Myers Collaborates With BNTX for Oncology Candidate
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
Read More
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.
Read More
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Read More
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The companies will work on transforming outcomes for patients with difficult-to-treat solid tumors, Boerner said.
Read More
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Read More
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Published: June 02, 2025 by: Market Watch
Sentiment: Positive
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
Read More
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MAINZ, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody.
Read More
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
Read More
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
Read More
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears safe as well, as observed in the management's recent payout hike and the still rich cash flows despite the ongoing patent cliff impact. This is on top of the raised FY2025 guidance, given the accelerating Growth Portfolio revenue profile compared to a year ago, thanks to the M&A activities and intensified R&D efforts.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield, and nearly 6% dividend make it a compelling income play, even amid pipeline concerns. Valuation is attractive: a sub-7x forward P/E and high dividend yield more than discount muted growth and generic competition risks.
Read More
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Positive
Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted EPS guidance from $6.55-$6.85 to $6.7-$7, as well as revenue expectations from $45.5 billion to $45.8-$46.8 billion. Bristol-Myers Squibb's key franchises remain oncology and cardiovascular, primarily due to the strong performance of Opdivo, Camzyos, and Reblozyl.
Read More
When It Rains Gold, Put Out The Bucket: 2 Wonderful Income Bargains
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Focus on high-quality, dividend-paying stocks with temporary setbacks, offering both value and income for patient investors. Bristol-Myers Squibb is deeply undervalued, carries a 5.3% yield, strong profitability, and a promising neurodegenerative drug pipeline. Rexford Industrial Realty offers a 5% yield, benefits from supply-constrained Southern California industrial markets, and trades far below historical valuation.
Read More
Avoid These Dividend Disasters Before It's Too Late
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Negative
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Read More
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline.
Read More
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
Read More
Buy These 2 Beaten Down Stocks Now Before They Rally
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headwinds, but offer attractive entry points for patient investors seeking multi-year recovery and income. AAT is undervalued due to office exposure and California concentration, but has solid financials, a safe dividend, and multifamily growth potential.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42% and forward dividend income reaching $2,195.04. Added to positions in Bristol-Myers Squibb, Pfizer, and BP, focusing on undervalued stocks with strong dividend yields and growth potential.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Dr. Christopher S. Boerner Ph.D.
- Employees 34100